-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to a report released by the World Health Organization’s International Agency for Research on Cancer (IARC), China’s new cancer cases will be 4.
58% in 2020, an increase of 4.
58% year-on-year, and women’s new cancers accounted for 45.
73%.
58% in 2020, an increase of 4.
58% year-on-year, and women’s new cancers accounted for 45.
73%.
With the rapid development of targeted drugs, chemotherapeutic drug delivery methods and routes have gradually improved, and drug intervention has become an important means of cervical cancer treatment.
Chemotherapy is gradually participating in the comprehensive treatment of cervical cancer in the form of neoadjuvant, simultaneous, auxiliary and palliative.
Cervical cancer chemotherapy is based on cisplatin-based combination chemotherapy.
Targeted therapy with biological drug bevacizumab intervention has further improved the quality of life of patients with recurrent and metastatic cervical cancer.
The application of new targeted drugs and immunosuppressive agents is already in clinical development.
In recent years, after the human papillomavirus (HPV) vaccine was launched in my country, the market is booming and the supply exceeds demand.
Chemotherapy is gradually participating in the comprehensive treatment of cervical cancer in the form of neoadjuvant, simultaneous, auxiliary and palliative.
Cervical cancer chemotherapy is based on cisplatin-based combination chemotherapy.
Targeted therapy with biological drug bevacizumab intervention has further improved the quality of life of patients with recurrent and metastatic cervical cancer.
The application of new targeted drugs and immunosuppressive agents is already in clinical development.
In recent years, after the human papillomavirus (HPV) vaccine was launched in my country, the market is booming and the supply exceeds demand.
Bevacizumab
Global growth of biosimilars by 635% in2020
Bevacizumab is a targeted biological agent developed by Roche, under the trade name Avastin.
It was first approved by the US FDA in February 2004 to be used in combination with 5-fluorouracil chemotherapy for the treatment of patients with metastatic colorectal cancer.
It is the world's first approved drug targeting VEGF.
After that, it has been approved for multiple indications such as non-small cell lung cancer, kidney cancer, glioma, ovarian cancer, and cervical cancer.
It was first approved by the US FDA in February 2004 to be used in combination with 5-fluorouracil chemotherapy for the treatment of patients with metastatic colorectal cancer.
It is the world's first approved drug targeting VEGF.
After that, it has been approved for multiple indications such as non-small cell lung cancer, kidney cancer, glioma, ovarian cancer, and cervical cancer.
In 2019, Roche's Avastin's global market sales reached a peak of 7.
073 billion Swiss francs, a year-on-year increase of 3.
27%.
After the expiration of the patent for bevacizumab single antigen research, biosimilar drugs were launched on the market.
In 2020, Amgen’s Mvasi and Pfizer’s Zirabev had sales of US$941 million, an increase of 635.
16% over the previous year.
073 billion Swiss francs, a year-on-year increase of 3.
27%.
After the expiration of the patent for bevacizumab single antigen research, biosimilar drugs were launched on the market.
In 2020, Amgen’s Mvasi and Pfizer’s Zirabev had sales of US$941 million, an increase of 635.
16% over the previous year.
Local products have a place right after they hit the market
In recent years, the domestic monoclonal antibody drug market has grown rapidly.
According to data from Minai.
com, in the first three quarters of 2020, the amount of terminal medications for antibody drugs in public hospitals in key provinces and cities in China reached 6.
044 billion yuan, an increase of 13.
96% over the same period of the previous year.
In 2020, domestic sales of monoclonal antibody drugs have reached more than 20 billion yuan.
According to data from Minai.
com, in the first three quarters of 2020, the amount of terminal medications for antibody drugs in public hospitals in key provinces and cities in China reached 6.
044 billion yuan, an increase of 13.
96% over the same period of the previous year.
In 2020, domestic sales of monoclonal antibody drugs have reached more than 20 billion yuan.
On December 6, 2019, the State Food and Drug Administration approved Qilu Pharmaceutical’s bevacizumab injection to be marketed under the trade name Amko; on June 17, 2020, Cinda Biopharmaceutical (Suzhou)’s bevacizumab injection Anti-injection was approved to be marketed under the trade name of Dayotong.
In the first three quarters of 2020, the amount of bevacizumab used in public hospitals in key provinces and cities in China reached 1.
208 billion yuan, an increase of 14.
94% over the previous year.
Among them, Roche's Avastin accounted for 77.
18%, Qilu Pharmaceutical's Anta accounted for 22.
75%, and Cinda Biopharmaceutical (Suzhou)'s Dayoutong accounted for 0.
07%.
208 billion yuan, an increase of 14.
94% over the previous year.
Among them, Roche's Avastin accounted for 77.
18%, Qilu Pharmaceutical's Anta accounted for 22.
75%, and Cinda Biopharmaceutical (Suzhou)'s Dayoutong accounted for 0.
07%.
HPV vaccine
Jiadaxiu accounts for 95% of the global HPV vaccine market
With the global pandemic of the new coronavirus in 2020, mankind has a new understanding of vaccines, which has promoted the continuous growth of the global vaccine market.
The latest data shows that in 2020, the five major global vaccine companies GSK, MSD, Pfizer, Sanofi, and Astra Zeneca will have sales revenue of US$30.
5 billion, an increase of 3.
26% year-on-year.
The latest data shows that in 2020, the five major global vaccine companies GSK, MSD, Pfizer, Sanofi, and Astra Zeneca will have sales revenue of US$30.
5 billion, an increase of 3.
26% year-on-year.
Cervical cancer vaccine, also known as HPV vaccine or human papilloma virus vaccine, is a vaccine to prevent female cervical cancer, human genital cancer and genital warts.
Based on the good clinical protection effect and safety data of HPV vaccine, the World Health Organization encourages the use of HPV vaccine in suitable populations to reduce the incidence of cervical cancer.
Based on the good clinical protection effect and safety data of HPV vaccine, the World Health Organization encourages the use of HPV vaccine in suitable populations to reduce the incidence of cervical cancer.
The US Merck & Co.
has developed the world's first HPV4-valent vaccine "Gardasil" (Gardasil), and has passed priority approval for listing in the United States.
Subsequently, the British company GlaxoSmithKline also produced the bivalent cervical cancer vaccine Cervarix.
has developed the world's first HPV4-valent vaccine "Gardasil" (Gardasil), and has passed priority approval for listing in the United States.
Subsequently, the British company GlaxoSmithKline also produced the bivalent cervical cancer vaccine Cervarix.
After the HPV 4-valent vaccine "Jia Daxiu" was approved for marketing, it became popular all over the world for a while, and it can prevent HPV6, 11, 16, and 18 diseases caused by four human papillomaviruses .
On December 10, 2014, the FDA approved Merck’s nine-valent recombinant cervical cancer vaccine, which became a replacement for Jiadaxiu 4.
Jiadaxiu 9 can prevent and treat human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58, thus becoming the main product in the global HPV vaccine market.
On December 10, 2014, the FDA approved Merck’s nine-valent recombinant cervical cancer vaccine, which became a replacement for Jiadaxiu 4.
Jiadaxiu 9 can prevent and treat human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58, thus becoming the main product in the global HPV vaccine market.
In 2020, the global sales of recombinant cervical cancer vaccines reached US$4.
118 billion, an increase of 8.
11% over the previous year.
Jiadaxiu accounted for 95.
63%; GlaxoSmithKline’s bivalent vaccine Cervarix accounted for 4.
37%.
118 billion, an increase of 8.
11% over the previous year.
Jiadaxiu accounted for 95.
63%; GlaxoSmithKline’s bivalent vaccine Cervarix accounted for 4.
37%.
The Chinese market has recovered in the second half of 2020
On July 12, 2016, the State Food and Drug Administration approved GlaxoSmithKline’s application for import registration of a recombinant bivalent vaccine for cervical cancer that is a preventive biological product.
This product is a bivalent vaccine prepared by using a baculovirus expression system to express recombinant HPV 16 and 18 L1 virus-like particles, and after purification, adding MPL and aluminum hydroxide adjuvants, it becomes the first HPV vaccine to be marketed in China.
Research data shows that its safety and effectiveness in domestic target populations are consistent with those abroad.
This product is a bivalent vaccine prepared by using a baculovirus expression system to express recombinant HPV 16 and 18 L1 virus-like particles, and after purification, adding MPL and aluminum hydroxide adjuvants, it becomes the first HPV vaccine to be marketed in China.
Research data shows that its safety and effectiveness in domestic target populations are consistent with those abroad.
On May 18, 2017, the State Food and Drug Administration approved the listing of Merck’s recombinant cervical cancer quadrivalent vaccine under the trade name Jiadaxiu.
On April 28, 2018, the State Food and Drug Administration has conditionally approved Merck's recombinant cervical cancer 9-valent vaccine to market.
On April 28, 2018, the State Food and Drug Administration has conditionally approved Merck's recombinant cervical cancer 9-valent vaccine to market.
In January 2020, China's first domestically produced recombinant cervical cancer bivalent vaccine was approved, and it was marketed by Xiamen Wantai Canghai Biotech under the trade name Xinkening.
The domestic recombinant cervical cancer bivalent vaccine can cover cervical cancer, anal cancer, oropharyngeal cancer and rarer genital-related cancers caused by human papillomavirus.
The domestic recombinant cervical cancer bivalent vaccine can cover cervical cancer, anal cancer, oropharyngeal cancer and rarer genital-related cancers caused by human papillomavirus.
According to data from Minai.
com, in the first three quarters of 2020, the cervical cancer vaccination market in public hospitals in key provinces and cities in China is nearly 80 million yuan, an increase of 37.
45% over the same period of the previous year.
The Jiadaxiu 9-valent vaccine accounted for 45.
22%, the Jiadaxiu 4-valent vaccine accounted for 40.
27%, and the Cyrex bivalent vaccine accounted for 14.
51%.
com, in the first three quarters of 2020, the cervical cancer vaccination market in public hospitals in key provinces and cities in China is nearly 80 million yuan, an increase of 37.
45% over the same period of the previous year.
The Jiadaxiu 9-valent vaccine accounted for 45.
22%, the Jiadaxiu 4-valent vaccine accounted for 40.
27%, and the Cyrex bivalent vaccine accounted for 14.
51%.
Affected by the epidemic in the fourth quarter of 2019 and the first quarter of 2020, cervical cancer vaccines showed negative growth, and the market has recovered in the second half of 2020.
According to a report released by the World Health Organization’s International Agency for Research on Cancer (IARC), China’s new cancer cases will be 4.
58% in 2020, an increase of 4.
58% year-on-year, and women’s new cancers accounted for 45.
73%.
58% in 2020, an increase of 4.
58% year-on-year, and women’s new cancers accounted for 45.
73%.
With the rapid development of targeted drugs, chemotherapeutic drug delivery methods and routes have gradually improved, and drug intervention has become an important means of cervical cancer treatment.
Chemotherapy is gradually participating in the comprehensive treatment of cervical cancer in the form of neoadjuvant, simultaneous, auxiliary and palliative.
Cervical cancer chemotherapy is based on cisplatin-based combination chemotherapy.
Targeted therapy with biological drug bevacizumab intervention has further improved the quality of life of patients with recurrent and metastatic cervical cancer.
The application of new targeted drugs and immunosuppressive agents is already in clinical development.
In recent years, after the human papillomavirus (HPV) vaccine was launched in my country, the market is booming and the supply exceeds demand.
Chemotherapy is gradually participating in the comprehensive treatment of cervical cancer in the form of neoadjuvant, simultaneous, auxiliary and palliative.
Cervical cancer chemotherapy is based on cisplatin-based combination chemotherapy.
Targeted therapy with biological drug bevacizumab intervention has further improved the quality of life of patients with recurrent and metastatic cervical cancer.
The application of new targeted drugs and immunosuppressive agents is already in clinical development.
In recent years, after the human papillomavirus (HPV) vaccine was launched in my country, the market is booming and the supply exceeds demand.
Bevacizumab
Global growth of biosimilars by 635% in 2020
Bevacizumab is a targeted biological agent developed by Roche, under the trade name Avastin.
It was first approved by the US FDA in February 2004 to be used in combination with 5-fluorouracil chemotherapy for the treatment of patients with metastatic colorectal cancer.
It is the world's first approved drug targeting VEGF.
After that, it has been approved for multiple indications such as non-small cell lung cancer, kidney cancer, glioma, ovarian cancer, and cervical cancer.
It was first approved by the US FDA in February 2004 to be used in combination with 5-fluorouracil chemotherapy for the treatment of patients with metastatic colorectal cancer.
It is the world's first approved drug targeting VEGF.
After that, it has been approved for multiple indications such as non-small cell lung cancer, kidney cancer, glioma, ovarian cancer, and cervical cancer.
In 2019, Roche's Avastin's global market sales reached a peak of 7.
073 billion Swiss francs, a year-on-year increase of 3.
27%.
After the expiration of the patent for bevacizumab single antigen research, biosimilar drugs were launched on the market.
In 2020, Amgen’s Mvasi and Pfizer’s Zirabev had sales of US$941 million, an increase of 635.
16% over the previous year.
073 billion Swiss francs, a year-on-year increase of 3.
27%.
After the expiration of the patent for bevacizumab single antigen research, biosimilar drugs were launched on the market.
In 2020, Amgen’s Mvasi and Pfizer’s Zirabev had sales of US$941 million, an increase of 635.
16% over the previous year.
Local products have a place right after they hit the market
In recent years, the domestic monoclonal antibody drug market has grown rapidly.
According to data from Minai.
com, in the first three quarters of 2020, the amount of terminal medications for antibody drugs in public hospitals in key provinces and cities in China reached 6.
044 billion yuan, an increase of 13.
96% over the same period of the previous year.
In 2020, domestic sales of monoclonal antibody drugs have reached more than 20 billion yuan.
According to data from Minai.
com, in the first three quarters of 2020, the amount of terminal medications for antibody drugs in public hospitals in key provinces and cities in China reached 6.
044 billion yuan, an increase of 13.
96% over the same period of the previous year.
In 2020, domestic sales of monoclonal antibody drugs have reached more than 20 billion yuan.
On December 6, 2019, the State Food and Drug Administration approved Qilu Pharmaceutical’s bevacizumab injection to be marketed under the trade name Amko; on June 17, 2020, Cinda Biopharmaceutical (Suzhou)’s bevacizumab injection Anti-injection was approved to be marketed under the trade name of Dayotong.
In the first three quarters of 2020, the amount of bevacizumab used in public hospitals in key provinces and cities in China reached 1.
208 billion yuan, an increase of 14.
94% over the previous year.
Among them, Roche's Avastin accounted for 77.
18%, Qilu Pharmaceutical's Anta accounted for 22.
75%, and Cinda Biopharmaceutical (Suzhou)'s Dayoutong accounted for 0.
07%.
208 billion yuan, an increase of 14.
94% over the previous year.
Among them, Roche's Avastin accounted for 77.
18%, Qilu Pharmaceutical's Anta accounted for 22.
75%, and Cinda Biopharmaceutical (Suzhou)'s Dayoutong accounted for 0.
07%.
HPV vaccine
Jiadaxiu accounts for 95% of the global HPV vaccine market
With the global pandemic of the new coronavirus in 2020, mankind has a new understanding of vaccines, which has promoted the continuous growth of the global vaccine market.
The latest data shows that in 2020, the five major global vaccine companies GSK, MSD, Pfizer, Sanofi, and Astra Zeneca will have sales revenue of US$30.
5 billion, an increase of 3.
26% year-on-year.
The latest data shows that in 2020, the five major global vaccine companies GSK, MSD, Pfizer, Sanofi, and Astra Zeneca will have sales revenue of US$30.
5 billion, an increase of 3.
26% year-on-year.
Cervical cancer vaccine, also known as HPV vaccine or human papilloma virus vaccine, is a vaccine to prevent female cervical cancer, human genital cancer and genital warts.
Based on the good clinical protection effect and safety data of HPV vaccine, the World Health Organization encourages the use of HPV vaccine in suitable populations to reduce the incidence of cervical cancer.
Based on the good clinical protection effect and safety data of HPV vaccine, the World Health Organization encourages the use of HPV vaccine in suitable populations to reduce the incidence of cervical cancer.
The US Merck & Co.
has developed the world's first HPV4-valent vaccine "Gardasil" (Gardasil), and has passed priority approval for listing in the United States.
Subsequently, the British company GlaxoSmithKline also produced the bivalent cervical cancer vaccine Cervarix.
has developed the world's first HPV4-valent vaccine "Gardasil" (Gardasil), and has passed priority approval for listing in the United States.
Subsequently, the British company GlaxoSmithKline also produced the bivalent cervical cancer vaccine Cervarix.
After the HPV 4-valent vaccine "Jia Daxiu" was approved for marketing, it became popular all over the world for a while, and it can prevent HPV6, 11, 16, and 18 diseases caused by four human papillomaviruses .
On December 10, 2014, the FDA approved Merck’s nine-valent recombinant cervical cancer vaccine, which became a replacement for Jiadaxiu 4.
Jiadaxiu 9 can prevent and treat human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58, thus becoming the main product in the global HPV vaccine market.
On December 10, 2014, the FDA approved Merck’s nine-valent recombinant cervical cancer vaccine, which became a replacement for Jiadaxiu 4.
Jiadaxiu 9 can prevent and treat human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58, thus becoming the main product in the global HPV vaccine market.
In 2020, the global sales of recombinant cervical cancer vaccines reached US$4.
118 billion, an increase of 8.
11% over the previous year.
Jiadaxiu accounted for 95.
63%; GlaxoSmithKline’s bivalent vaccine Cervarix accounted for 4.
37%.
118 billion, an increase of 8.
11% over the previous year.
Jiadaxiu accounted for 95.
63%; GlaxoSmithKline’s bivalent vaccine Cervarix accounted for 4.
37%.
The Chinese market has recovered in the second half of 2020
On July 12, 2016, the State Food and Drug Administration approved GlaxoSmithKline’s application for import registration of a recombinant bivalent vaccine for cervical cancer that is a preventive biological product.
This product is a bivalent vaccine prepared by using a baculovirus expression system to express recombinant HPV 16 and 18 L1 virus-like particles, and after purification, adding MPL and aluminum hydroxide adjuvants, it becomes the first HPV vaccine to be marketed in China.
Research data shows that its safety and effectiveness in domestic target populations are consistent with those abroad.
This product is a bivalent vaccine prepared by using a baculovirus expression system to express recombinant HPV 16 and 18 L1 virus-like particles, and after purification, adding MPL and aluminum hydroxide adjuvants, it becomes the first HPV vaccine to be marketed in China.
Research data shows that its safety and effectiveness in domestic target populations are consistent with those abroad.
On May 18, 2017, the State Food and Drug Administration approved the listing of Merck’s recombinant cervical cancer quadrivalent vaccine under the trade name Jiadaxiu.
On April 28, 2018, the State Food and Drug Administration has conditionally approved Merck's recombinant cervical cancer 9-valent vaccine to market.
On April 28, 2018, the State Food and Drug Administration has conditionally approved Merck's recombinant cervical cancer 9-valent vaccine to market.
In January 2020, China's first domestically produced recombinant cervical cancer bivalent vaccine was approved, and it was marketed by Xiamen Wantai Canghai Biotech under the trade name Xinkening.
The domestic recombinant cervical cancer bivalent vaccine can cover cervical cancer, anal cancer, oropharyngeal cancer and rarer genital-related cancers caused by human papillomavirus.
The domestic recombinant cervical cancer bivalent vaccine can cover cervical cancer, anal cancer, oropharyngeal cancer and rarer genital-related cancers caused by human papillomavirus.
According to data from Minai.
com, in the first three quarters of 2020, the cervical cancer vaccination market in public hospitals in key provinces and cities in China is nearly 80 million yuan, an increase of 37.
45% over the same period of the previous year.
The Jiadaxiu 9-valent vaccine accounted for 45.
22%, the Jiadaxiu 4-valent vaccine accounted for 40.
27%, and the Cyrex bivalent vaccine accounted for 14.
51%.
com, in the first three quarters of 2020, the cervical cancer vaccination market in public hospitals in key provinces and cities in China is nearly 80 million yuan, an increase of 37.
45% over the same period of the previous year.
The Jiadaxiu 9-valent vaccine accounted for 45.
22%, the Jiadaxiu 4-valent vaccine accounted for 40.
27%, and the Cyrex bivalent vaccine accounted for 14.
51%.
Affected by the epidemic in the fourth quarter of 2019 and the first quarter of 2020, cervical cancer vaccines showed negative growth, and the market has recovered in the second half of 2020.
According to a report released by the World Health Organization’s International Agency for Research on Cancer (IARC), China’s new cancer cases will be 4.
58% in 2020, an increase of 4.
58% year-on-year, and women’s new cancers accounted for 45.
73%.
58% in 2020, an increase of 4.
58% year-on-year, and women’s new cancers accounted for 45.
73%.
With the rapid development of targeted drugs, chemotherapeutic drug delivery methods and routes have gradually improved, and drug intervention has become an important means of cervical cancer treatment.
Chemotherapy is gradually participating in the comprehensive treatment of cervical cancer in the form of neoadjuvant, simultaneous, auxiliary and palliative.
Cervical cancer chemotherapy is based on cisplatin-based combination chemotherapy.
Targeted therapy with biological drug bevacizumab intervention has further improved the quality of life of patients with recurrent and metastatic cervical cancer.
The application of new targeted drugs and immunosuppressive agents is already in clinical development.
In recent years, after the human papillomavirus (HPV) vaccine was launched in my country, the market is booming and the supply exceeds demand.
Chemotherapy is gradually participating in the comprehensive treatment of cervical cancer in the form of neoadjuvant, simultaneous, auxiliary and palliative.
Cervical cancer chemotherapy is based on cisplatin-based combination chemotherapy.
Targeted therapy with biological drug bevacizumab intervention has further improved the quality of life of patients with recurrent and metastatic cervical cancer.
The application of new targeted drugs and immunosuppressive agents is already in clinical development.
In recent years, after the human papillomavirus (HPV) vaccine was launched in my country, the market is booming and the supply exceeds demand.
Bevacizumab
BevacizumabGlobal growth of biosimilars by 635% in 2020
Global growth of biosimilars by 635% in 2020 Bevacizumab is a targeted biological agent developed by Roche, under the trade name Avastin.
It was first approved by the US FDA in February 2004 to be used in combination with 5-fluorouracil chemotherapy for the treatment of patients with metastatic colorectal cancer.
It is the world's first approved drug targeting VEGF.
After that, it has been approved for multiple indications such as non-small cell lung cancer, kidney cancer, glioma, ovarian cancer, and cervical cancer.
It was first approved by the US FDA in February 2004 to be used in combination with 5-fluorouracil chemotherapy for the treatment of patients with metastatic colorectal cancer.
It is the world's first approved drug targeting VEGF.
After that, it has been approved for multiple indications such as non-small cell lung cancer, kidney cancer, glioma, ovarian cancer, and cervical cancer.
In 2019, Roche's Avastin's global market sales reached a peak of 7.
073 billion Swiss francs, a year-on-year increase of 3.
27%.
After the expiration of the patent for bevacizumab single antigen research, biosimilar drugs were launched on the market.
In 2020, Amgen’s Mvasi and Pfizer’s Zirabev had sales of US$941 million, an increase of 635.
16% over the previous year.
073 billion Swiss francs, a year-on-year increase of 3.
27%.
After the expiration of the patent for bevacizumab single antigen research, biosimilar drugs were launched on the market.
In 2020, Amgen’s Mvasi and Pfizer’s Zirabev had sales of US$941 million, an increase of 635.
16% over the previous year.
Local products have a place right after they hit the market
Local products have a place right after they hit the market 。，20201-3 ，60.
44，13.
96%。2020200。
44，13.
96%。2020200。
2019126，，；2020617，（），。
20201-3，12.
08，14.
94%。，77.
18%，22.
75%，（）0.
07%。
08，14.
94%。，77.
18%，22.
75%，（）0.
07%。
HPV
HPV HPV95%
HPV95% 2020，，。，2020GSK、MSD、Pfizer、Sanofi、Astra Zeneca305，3.
26%。
26%。
HPV，。HPV，HPV。
HPV4“”（Gardasil），。，Cervarix。
HPV4“”，，HPV6、11、 16、18。20141210，FDA，4。96、11、16、18、31、33、45、5258，HPV。
202041.
18，8.
11%。95.
63%；（Cervarix）4.
37%。
18，8.
11%。95.
63%；（Cervarix）4.
37%。
2020
2020 2016712，。HPV1618L1，，MPL，HPV。，。
2017518，4，。2018428，9。
20201，，，。、、。
，20201-3 ，8000，37.
45%。945.
22%，440.
27%，14.
51%。
45%。945.
22%，440.
27%，14.
51%。
2019、2020，，2020。
